INTRODUCTION {#s1}
============

Cervical cancer is the second most common form of cancer diagnosed in women and the third leading cause of death from cancer. This accounts for approximately 8% of total cancer cases and cancer deaths in women \[[@R1]\]. In 2012, there were an estimated 527,600 new cervical cancer cases and 265,700 deaths from cervical cancer worldwide, mostly affecting developing countries \[[@R1]\]. Cervical cancer affects the cervix and encompasses squamous cell carcinomas (90%), adenocarcinoma (10%), and other subtypes \[[@R2], [@R3]\]. Currently, a combination of surgery, radiotherapy and chemotherapy is still the most effective form of treatment for cervical cancer \[[@R4]--[@R6]\]. However, any form of treatment inevitably implies severe trauma to the patient, as well as an economic burden and mental stress \[[@R7]--[@R9]\]. A variety of risk factors, such as chronic inflammation, unhealthy living conditions, and human papillomavirus (HPV) infections have been proven to increase the risk of cervical tumorigenesis \[[@R10]--[@R13]\]. However, although numerous epidemiological and molecular biology-related studies have been conducted, the precise effects of these factors on the process of tumorigenesis process are still poorly understood.

In the last decade, numerous studies have suggested that certain cytokines may play critical roles in the processes of inflammatory cell infiltration and malignant cell transformation \[[@R14], [@R15]\]. Interleukin-10 (IL-10) is a multifunctional cytokine that is mainly secreted by T helper type2 cells (Th2 cells), monocytes/macrophages, keratinocytes and tumor cells as well, as well as human helpertype2 cells (Th1 cells) \[[@R16], [@R17]\]. IL-10 exhibits complex biological effects, including the capacity to stimulate mast cells maturation and accelerate the proliferation and differentiation of B cells, restrain type 1 immune responses by inhibiting the production of cytokines such as IL-2, IFN-gamma, and other cytokines, decrease the IFN-gamma production by natural killer cells and interfere with macrophage activation \[[@R18]\]. IL-10 exhibits a dual role during cancer development, inducing both cancer-promoting (immunosuppressive) and cancer-inhibiting (anti-angiogenic) effects \[[@R19]\].

Single nucleotide polymorphisms are one of the most common, heritable variations in the human genome, accounting for more than 90% of all variation \[[@R20]\]. The IL-10 gene is located on chromosome 1q31-32, which spans 4.8 kb, and contains 5 exons and 4 introns that encode 178 amino acids \[[@R21]\]. To date, at least 50 polymorphic loci have been reported, such as -2849, -2776, -2769 and -2763 \[[@R22]\]. The three most common SNPs in the IL-10 promoter region that have been reported to significantly influence gene transcription and expression are -1082A \> G (rs1800870), -819T \> C (rs1800871) and -592C \> A (rs1800872) \[[@R23]\]. Some molecular research has shown that these polymorphisms can influence and/or change the susceptibility of individuals to different forms of cancer, such as head and neck cancer, gastric cancer, leukemia, and others \[[@R24]--[@R26]\]. In 2001, Stanczuk et al. published the first case-control study examining the effects of the IL-10 -1082A \> G polymorphism on cervical cancer risk, and the results suggested that African women with an AG genotype were at an increased risk for cervical cancer \[[@R27]\]. To date, two meta-analyses have been conducted, examining previously published studies to elucidate the association between IL-10 polymorphisms and cervical cancer risk \[[@R28], [@R29]\]. However, these meta-analyses have not been comprehensive and have not yielded consistent results.

Therefore, we conducted the present meta-analysis to provide a more precise and comprehensive assessment of the relationship between IL-10 polymorphisms and cervical cancer susceptibility. This meta-analysis was performed according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@R30]\]. No ethical issues were implicated in this study because our data were based on previously published reports.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Initially, 164 relevant articles were identified through our search strategy. The study selection procession is shown in Figure [1](#F1){ref-type="fig"}. After a comprehensive review, 86 articles were excluded because they were duplicate studies. After screening the title and the abstract, the full text of each article was analyzed. Eventually, 17 published articles (29 studies including polymorphisms at three different loci) involving 4,037 patients and 3,249 controls were included in this meta-analysis \[[@R27], [@R31]--[@R46]\]. Thirteen studies focused on the relationship between the -1082A \> G polymorphism and cervical cancer risk \[[@R27], [@R31]--[@R42]\], six studies focused on the relationship between the -819T \> C polymorphism and cervical cancer risk \[[@R31], [@R38]--[@R40], [@R42], [@R43]\], and ten studies focused on the relationship between the -592C \> A polymorphism and cervical cancer risk \[[@R31], [@R33], [@R35], [@R38]--[@R40], [@R42], [@R44]--[@R46]\]. There were 10 articles that included 1,382 cases and 1,602 controls from Asian populations \[[@R31], [@R34]--[@R36], [@R38], [@R41]--[@R43], [@R45], [@R46]\], 5 articles that included 2,381 cases and 1,396 controls from Caucasian populations \[[@R33], [@R37], [@R39], [@R40], [@R44]\], and 2 articles that included 274 cases and 251 controls from African populations \[[@R27], [@R32]\]. Regarding the genotyping method, PCR was used in 13 studies (including ARMS-PCR, PCR-RFLP, PCR Pyrosequencing and Multiplex PCR techniques) \[[@R27], [@R31], [@R32], [@R34]--[@R38], [@R42]--[@R46]\], 4 studies reported using the Taqman method \[[@R33], [@R39]--[@R41]\]. The HWE values were calculated based on the genotype distributions of the groups. Some studies deviated from HWE for the IL-10 -1082A \> G polymorphism (four studies), -819T \> C polymorphism (two studies) and -592C \> A polymorphism (one study). A summary of the characteristics of the included studies is shown in Table [1](#T1){ref-type="table"}.

![Flow diagram of the study selection process](oncotarget-09-12365-g001){#F1}

###### Characteristics of case-control studies on IL-10 -1082A \> G, -819T \> C and -592C \> A polymorphisms and cervical cancer risk

  First author    Year   Country        Racial descent   Source of controls   Case   Control   Genotype distribution   *P* for HWE^a^   Genotyping method   NOS                                             
  --------------- ------ -------------- ---------------- -------------------- ------ --------- ----------------------- ---------------- ------------------- ----- ----- ----- -------- -------------------- ---
  Stanczuk        2001   Zimbabwe       African          HB                   77     69        45                      31               1                   58    11    0     0.472    ARMS-PCR             6
  Roh             2002   Korea          Asian            HB                   144    179       144                     0                0                   179   0     0     NA       PCR-RFLP             4
  Govan           2003   South Africa   African          HB                   197    182       88                      80               29                  76    65    41    \<0.01   ARMS-PCR             6
  Zoodsma         2005   Netherlands    Caucasian        PB                   667    606       154                     326              187                 130   307   169   0.668    Taqman               9
  Matsumoto       2010   Japanese       Asian            HB                   104    173       73                      26               5                   156   16    1     0.412    ARMS-PCR             7
  Yu              2011   China          Asian            HB                   103    115       90                      12               1                   98    14    3     0.012    ARMS-PCR             6
  Wang            2011   China          Asian            PB                   186    200       77                      85               24                  103   76    21    0.222    PCR                  7
  Barbisan        2012   Argentina      Caucasian        HB                   122    176       50                      61               11                  79    83    14    0.222    PCR Pyrosequencing   6
  Singhal         2015   India          Asian            HB                   208    250       32                      76               100                 100   107   43    0.125    PCR-RFLP             7
  Zidi            2015   Tunisian       Caucasian        HB                   86     126       33                      36               17                  51    50    25    0.055    TaqMan               6
  Torres-Poveda   2015   Mexico         Caucasian        HB                   200    200       121                     70               9                   110   78    12    0.708    TaqMan               8
  Zeng            2015   China          Asian            HB                   52     50        5                       7                40                  24    22    0     0.033    TaqMan               5
  Bai             2016   China          Asian            HB                   165    165       74                      75               16                  80    72    13    0.563    PCR-RFLP             7
                                                                                               TT                      TC               CC                  TT    TC    CC                                  
  Roh             2002   Korea          Asian            HB                   144    179       77                      56               11                  87    77    15    0.724    PCR-RFLP             6
  Singh           2009   India.         Asian            HB                   150    162       27                      67               56                  24    61    77    0.046    PCR-RFLP.            6
  Singhal         2015   India          Asian            HB                   208    250       61                      102              45                  61    120   69    0.537    PCR-RFLP             7
  Zidi            2015   Tunisian       Caucasian        HB                   86     126       9                       32               45                  4     66    56    0.003    TaqMan               5
  Torres-Poveda   2016   Mexico         Caucasian        HB                   200    200       54                      97               49                  34    85    81    0.156    TaqMan               8
  Bai             2016   China          Asian            HB                   165    165       44                      75               45                  28    73    64    0.362    PCR-RFLP             7
                                                                                               CC                      CA               AA                  CC    CA    AA                                  
  Roh             2002   Korea          Asian            HB                   144    179       11                      56               77                  15    77    87    0.724    PCR-RFLP             6
  Zoodsma         2005   Netherlands    Caucasian        PB                   667    606       393                     231              30                  405   175   26    0.206    Taqman               9
  Ivansson        2007   Sweden         Caucasian        PB                   1306   288       736                     464              82                  162   112   14    0.334    Multiplex PCR        7
  Xiong           2010   China          Asian            PB                   70     108       12                      23               35                  13    44    51    0.467    PCR-RFLP             8
  Yu              2011   China          Asian            HB                   103    115       7                       37               59                  19    44    52    0.075    ARMS-PCR             7
  Shekari         2012   India.         Asian            PB                   200    200       16                      96               88                  17    102   81    0.054    PCR-RFLP             7
  Singhal         2015   India          Asian            HB                   208    250       85                      94               29                  60    123   67    0.810    PCR-RFLP             7
  Zidi            2015   Tunisian       Caucasian        HB                   86     126       45                      32               9                   57    64    5     0.012    TaqMan               5
  Torres-Poveda   2016   Mexico         Caucasian        HB                   200    200       44                      98               58                  85    85    30    0.255    TaqMan               8
  Bai             2016   China          Asian            HB                   165    165       20                      82               63                  15    80    70    0.243    PCR-RFLP             7

^a^HWE in control, PB: Population-base control, HB: Hospital-base control and/or healthy base control

Association between the IL-10 -1082A \> G polymorphism and cervical cancer risk {#s2_2}
-------------------------------------------------------------------------------

A total of thirteen relevant studies, consisting of 2,311 patients and 2,491 controls focused on the association between the IL-10 -1082A \> G polymorphism and cervical cancer risk. Overall, a significantly increased risk of cervical cancer was observed in three genetic models (G vs. A: OR = 1.60, 95% CI = 1.12-2.29, *P* = 0.01, I^2^ = 92.3%; AG vs. AA: OR = 1.34, 95%CI = 1.04--1.74, *P* = 0.03, I^2^ = 65.9%; AG+GG vs. AA: OR = 1.58, 95% CI = 1.11--2.25, *P* = 0.02, I^2^ = 84.4%) ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}, Figure [2A](#F2){ref-type="fig"} for AG+GG vs. AA model). Subsequent subgroup analyses by ethnicity also revealed a similar risk in Asian populations in all five genetic models (G vs. A: OR = 2.41, 95% CI = 1.26--4.60, *P* = 0.01, I^2^ = 93.3%; AG vs. AA: OR = 1.64, 95% CI = 1.14--2.36, *P* = 0.01, I^2^ = 53.3%; GG vs. AA: OR = 3.75, 95% CI = 1.21--11.61, *P* = 0.02, I^2^ = 85.2%; AG+GG vs. AA: OR = 2.28, 95% CI = 1.27--4.10, *P* = 0.01, I^2^ = 84.6%,; GG vs. AA+AG: OR = 2.94, 95% CI = 1.08-8.03, *P* = 0.04, I^2^ = 83.7%). Moreover, a significant risk of cervical cancer was also seen in all five genetic models for the HWE, the hospital control and the PCR genotyping groups ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Heterogeneity was observed in all five genetic models. Meta-regression analyses were conducted, but the results failed to identify any factors contributing to the observed heterogeneity.

![Statistical analysis of the association between the IL-10 -1082A\>G polymorphism and cervical cancer risk in the AG+GG vs. AA model\
(**A**) ORs and 95% CIs; (**B**) cumulative analysis; (**C**) sensitivity analysis; (**D**) publication bias.](oncotarget-09-12365-g002){#F2}

A cumulative analysis by publication date demonstrated that cancer risk increased gradually and became positive following the study conducted by Singhal et al. in 2012 were included (Figure [2B](#F2){ref-type="fig"} for AG+GG vs. AA model). A sensitivity analysis revealed that no single study qualitatively changed the pooled ORs, indicating that the results of this meta-analysis were stable (Figure [2C](#F2){ref-type="fig"} for AG+GG vs. AA model).

Publication bias was assessed with Funnel plots. Plot asymmetry was observed only in the AG+GG vs. AA model, which was redressed in the subgroup analysis by ethnicity (Figure [2D](#F2){ref-type="fig"} for AG+GG vs. AA model). These results were further supported by Egger's tests (G vs. A: *P* = 0.12; AG vs. AA: *P* = 0.06; GG vs. AA: *P* = 0.34; AG+GG vs. AA: *P* = 0.03; GG vs. AA+AG: *P* = 0.46).

Association between the IL-10 -819T \> C polymorphism and cervical cancer risk {#s2_3}
------------------------------------------------------------------------------

Six studies involving 953 cases and 1,082 controls were included in this meta-analysis to assess the association between the IL-10 -819T \> C polymorphism and cervical cancer risk. Interestingly, all genetic models indicated that they confer a protective effect against cervical cancer occurrence (C vs. T, OR = 0.74, 95% CI = 0.65-0.84, *P* \< 0.01, I^2^ = 23.8%; TC vs. TT, OR = 0.76, 95%CI = 0.61-0.95, P = 0.02, I^2^ = 2.6%; CC vs. TT, OR = 0.53, 95% CI = 0.41-0.70, *P* \< 0.01, I^2^ = 0%; TC+CC vs. TT, OR = 0.68, 95%CI = 0.55-0.84, *P* \< 0.01, I^2^ = 0%; CC vs. TT+TC, OR = 0.71, 95%CI = 0.54--0.95, P = 0.02, I^2^ = 48.7%) ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}, Figure [3A](#F3){ref-type="fig"} for TC+CC vs. TT model). Furthermore, subgroup analyses based on HWE status, the ethnicity, the control design and the genotyping method all indicated the same protective effect ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

![Statistical analysis of the association between the IL-10 -819T\>C polymorphism and cervical cancer risk in the TC+CC vs. TT model\
(**A**) ORs and 95% CIs; (**B**) cumulative analysis; (**C**) sensitivity analysis; (**D**) publication bias.](oncotarget-09-12365-g003){#F3}

The cumulative analysis also indicated some change only in the recessive model (Figure [3B](#F3){ref-type="fig"} for TC+CC vs. TT model). A sensitivity analysis was conducted, and no conspicuous change in the pooled ORs was detected except in the recessive model (Figure [3C](#F3){ref-type="fig"} for TC+CC vs. TT model). Moreover, no publication bias was observed, indicating that the results were statistically robust (C vs. T: *P* = 0.23; TC vs. TT: *P* = 0.06; CC vs. TT: *P* = 0.96; TC+CC vs. TT: *P* = 0.11; CC vs. TT+TC: *P* = 0.26) (Figure [3D](#F3){ref-type="fig"} for TC+CC vs. TT model).

Association between the IL-10 -592C \> A polymorphism and cervical cancer risk {#s2_4}
------------------------------------------------------------------------------

For the IL-10 -592C \> A polymorphism, ten studies consisting of 3,149 cases and 2,237 controls were pooled in the meta-analysis to assess whether this IL-10 -592C \> A polymorphism was associated with cervical cancer risk. Overall, no significant association was observed in any of the five models ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}; Figure [4A](#F4){ref-type="fig"} for CA+AA vs. CC model). Only two genetic models (for AA vs. CC, OR = 1.86, 95% CI = 1.02-3.39, *P* = 0.04, I^2^ = 69.6%; for AA vs. CC+CA, OR = 1.62, 95%CI = 1.06-2.49, *P* = 0.03, I^2^ = 46.6%) revealed an increased risk for cervical cancer in the Caucasian population group. Additional subgroup analyses were conducted based on HWE status, the control design and the genotyping method, but no significant associations were observed. The pooled ORs did not exhibit any changes following sensitivity or cumulative analyses, and no publication bias was observed (Figure [4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"} for CA+AA vs. CC model). Moreover, no publication bias was observed (A vs. C: P = 0.96; CA vs. CC: P = 0.63; AA vs. CC: *P* = 0.58; CA+AA vs. CC: *P* = 0.82; AA vs. CC+CA: *P* = 0.34) (Figure [4D](#F4){ref-type="fig"} for CA+AA vs. CC model).

![Statistical analysis of the association between the IL-10 -592C\>A polymorphism and cervical cancer risk in the CA+AA vs. CC model\
(**A**) ORs and 95% CIs; (**B**) cumulative analysis; (**C**) sensitivity analysis; (**D**) publication bias.](oncotarget-09-12365-g004){#F4}

DISCUSSION {#s3}
==========

Genetic factors are now known to be important variables affecting the susceptibility of patients to various diseases and have been paid an increasing amount of attention \[[@R47], [@R48]\]. Inflammatory and immune cytokines play important roles during the process of tumorigenesis transition from normal epithelium to malignant tumors, and these cytokines can promote this process by inducing angiogenesis, compensatory cell proliferation, DNA damage, or the accumulation of gene mutations \[[@R49]\]. Gene mutations, especially polymorphisms in the promoter region, can affect the process of gene transcription, resulting in abnormal expression of the corresponding mRNAs and dysfunction of the expressed proteins. These mutations can also influence the susceptibility of individuals to cancer \[[@R50], [@R51]\].

Since 2001, a large number of molecular epidemiological case-control studies have been conducted to explore the association between IL-10 polymorphisms and cervical cancer risk, but the results have been inconsistent. In terms of the IL-10 -1082A \> G polymorphism, Singhal et al. reported a case-control study in an Indian population, the AG and GG genotypes may significantly increase the risk of cervical cancer development compared with the AA genotype (AG vs. AA: OR = 2.2, 95%CI = 1.35--3.64; GG vs. AA: OR = 7.26, 95% CI = 4.2-12.4) \[[@R38]\]. A similarly increased risk was also observed in other studies. In contrast, other studies reported a negative association between the IL-10--1082A \> G polymorphism and cervical cancer risk. For -819T \> C and -592C \> A polymorphisms, there is still controversy regarding the relationship between these two polymorphisms and cervical cancer susceptibility.

In 2013, Ni et al. published the first meta-analysis examining the association between IL-10 gene polymorphisms and cervical cancer risk. Their meta-analysis included eight studies comprising 1,498 cases and 1,608 controls for the IL-10 -1082A \> G polymorphism, as well as five studies involving 2,396 cases and 1,388 controls for the IL-10 -592C \> A polymorphism \[[@R28]\]. The researchers found that the IL-10 -592C \> A polymorphism was associated with an increased risk of cervical cancer development. No significant association was found for the IL-10 -1082A \> G polymorphism \[[@R28]\]. In 2014, Zhang et al. conducted another meta-analysis to evaluate the association between the IL-10 -1082A \> G polymorphism and cervical cancer risk. This study included eight case-control studies comprising 1,983 cases and 1,618 controls; they also reported no association between this polymorphism and cervical cancer susceptibility \[[@R29]\]. Moreover, the association between the IL-10--819T \> C polymorphism and cervical cancer risk was also explored in the subgroup analysis by Yu et al. in 2013. This analysis only included three case-control studies, with 1,895 subjects, and indicated that there was a positive association with cervical cancer in some genetic models \[[@R52]\].

Compared with the previous meta-analyses, our meta-analysis relied on a more scientifically sound retrieval strategy and included more research studies (seventeen publications involving 7,286 individuals) to accurately assess the associations between the IL-10 -1082A \> G, -819T \> C and -592C \> A polymorphisms and cervical cancer risk. Our results suggest that the IL-10--1082A \> G polymorphism may be associated with an increased risk of cervical cancer development. In contrast, the IL-10--819T \> C polymorphism may have a protective effect against cervical cancer development, especially in Asian populations. In the stratified analysis, the heterogeneity between the included IL-10--1082A \> G polymorphism studies was moderately, and successfully reduced by the subgroup analysis based on ethnicity. This suggests that ethnic diversity maybe a potential heterogeneity factor. Moreover, after conducting the sensitivity and publication bias analyses, no significant alterations or bias were observed for any of the three polymorphisms, presenting the stability of the results of our meta-analysis.

To our knowledge, this is the first meta-analysis to examine the association between IL-10 polymorphisms and cervical cancer risk, including the three most common polymorphic loci (IL-10 -1082A \> G, -819T \> C and -592C \> A). However, there are some limitations of this study that should be addressed. First, only seventeen publications were included in our meta-analysis. The limited number of studies and sample size for each polymorphic locus may reduce the reliability of the results and affect the assessment of associations between these IL-10 polymorphisms and cervical cancer susceptibility. Second, additional risk factors, such as smoking, drinking, and HPV infection, were not considered. The interactions between genetic and environmental factors and cancer development could not be evaluated in our analysis. Third, the association between the IL-10 -1082A \> G, -819T \> C and -592C \> A polymorphisms and cervical cancer risk were analyzed separately, and the influence of the haplotype and gene-gene interactions was not analyzed due to an insufficient amount of data. Fourth, the heterogeneity that exists between the IL-10--1082A \> G polymorphism studies could influence the current results and distort the conclusions. In this meta-regression analysis, we could not find the source of the heterogeneity, although it could be reduced in the subgroup analysis.

In summary, our meta-analysis suggests that the IL-10--1082A \> G and -819T \> C polymorphisms are associated with cervical cancer susceptibility, but with contradictory effects. In contrast, no significant association was found between the IL-10--592C \> A polymorphism and cervical cancer susceptibility.

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy {#s4_1}
--------------------------

A comprehensive literature search (up until June 1^st^, 2017) was independently performed by two of the authors, without restrictions on the geographic region or language of publications from the following online databases: PubMed, Embase, Science Citation Index (SCI), CNKI and Wanfang. References appearing in relevant reports and recent reviews were all screened to identify potential articles of interest. The search terms"Interleukin-10", "polymorphism" AND "cervical cancer", and the following search strategy were used (in PubMed, for example): \#1 Interleukin-10, \#2 IL-10, \#3 rs1800870, \#4 rs1800871, \#5 rs1800872, \#6 \#1 OR \#2 OR \#3 OR \#4 OR \#5, \#7 polymorphism, \#8 variant, \#9 mutation, \#10 \#7 OR \#8 OR \#9, \#11 cervical cancer, \#12 cervical tumor, \#13 cervical neoplasm, \#14 \#11 OR \#12 OR \#13, \#15 \#6 AND \#10 AND \#14.

Eligibility criteria {#s4_2}
--------------------

To be included in this study, publications had to meet the following inclusion criteria: 1) the study design had to be a case-control study (including retrospective or prospective studies); 2) the focus of the study had to be on IL-10 promoter polymorphisms (-1082A \> G, -819T \> C and -592C \> A); 3) the case group had to include women with cervical cancer and the control group had to consist of women without cervical cancer; 4) the reports had to include sufficient information on the frequency distribution of different genotypes in order to calculate the odds ratios (ORs) and 95% confidence intervals (CIs); and 5) in the case that there were duplicate studies, we included the most recent or those with the largest samples sizes.

Data extraction and quality evaluation {#s4_3}
--------------------------------------

Two investigators (Guo and Wen), independently extracted the following information from all of the included studies: first author, year of publication, study country or region where the study was performed, ethnicity (Asian, Caucasian or African), the source of the controls, the sample sizes of patients and controls, data on the frequency distribution of different genotypes, the Hardy-Weinberg equilibrium (HWE) for the controls, and the genotyping method. In addition, the modified Newcastle-Ottawa scale (NOS) was employed by the first two authors in order to evaluate the quality of the included studies \[[@R53]\]. The scores ranged from 0 points (worst) to 10 points (best). Studies with a score of 7 or higher were classified as high quality (Table [2](#T2){ref-type="table"}).

###### Scale for quality evaluation

  ------------------------------------------------------------------------------------------------------------------------------
  Criteria                                                                                                               Score
  ---------------------------------------------------------------------------------------------------------------------- -------
  **Representativeness of cases**\                                                                                       2\
   Consecutive/randomly selected cases with clearly defined sampling frame\                                              1\
   Not consecutive/randomly selected case or without clearly defined sampling frame\                                     0
   Not described                                                                                                         

  **Source of controls**\                                                                                                2\
   Population-base control\                                                                                              1\
   Hospital-base control and/or healthy base control\                                                                    0
   Not described                                                                                                         

  **Hardy-Weinberg equilibrium in controls**\                                                                            2\
   Hardy-Weinberg equilibrium\                                                                                           1\
   Hardy-Weinberg disequilibrium\                                                                                        0
   Not available                                                                                                         

  **Genotyping examination**\                                                                                            2\
   Genotyping done under "blinded" condition and repeated again\                                                         1\
   Genotyping done under "blinded" condition or repeated again\                                                          0
   Unblinded done or not mentioned and unrepeated                                                                        

  **Association assessment**\                                                                                            2\
   Assess association between genotypes and cancer with appropriate statistics and adjustment for confounders\           1\
   Assess association between genotypes and cancer with appropriate statistics and without adjustment for confounders\   0
   Inappropriate statistics used                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------

Statistical analysis {#s4_4}
--------------------

ORs with 95% CIs were calculated to assess the strength of the association between the IL-10 -1082A \> G, -819T \> C and -592C \> A polymorphisms and cervical cancer susceptibility. For the IL-10 -1082A \> G polymorphism, the five following genetic models were used: allele contrast model (G vs. A), co-dominant models (AG vs. AA and GG vs. AA), dominant model (AG+GG vs. AA), and recessive model (GG vs. AA+AG). The same genetic models were also used to assess the IL-10 -819T \> C and -592C \> A polymorphisms. Subgroup analyses were performed according to HWE status, ethnicity difference, control designs, and genotyping methods. Heterogeneity between studies was determined via a Cochran's *Q* test and the I^2^ statistic \[[@R54]\]. A fixed-effect model (the Mantel-Haenszel method) was used when the *P*-value was more than 0.10 and the I^2^ was less than 40% \[[@R55]\]. Otherwise, a random-effects model (the DerSimonian and Laird method) was adopted \[[@R56]\]. Meta-regression analyses were conducted to explore the potential factors that contribute to heterogeneity. Furthermore, cumulative meta-analyses were conducted to observe whether the trend changed with the addition of studies. Sensitivity analyses were also conducted to evaluate the robustness of our results. Egger's linear regression and Begg's funnel plots were used to examine any potential publication bias \[[@R57], [@R58]\]. All statistical calculations were performed with STATA version 14.0 (Stata Corporation, College Station, TX, USA). A two-sided *P* value \< 0.05 was considered significant.
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